DMAC - NASDAQ
DiaMedica Therapeutics Inc.
$5.70
-1.2%DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
At a Glance
Live SnapshotDiaMedica Therapeutics Inc. Management Team
Mr. David J. Wambeke
Chief Business Officer
Mr. Dominic R. Cundari
Chief Commercial Officer
Dr. Alex Aimetti Ph.D.
Chief Development Officer
Mr. Scott Kellen CPA
Chief Financial Officer & Corporate Secretary
Compensation
$539,434
Dr. Lorianne K. Masuoka M.D.
Chief Medical Officer
Compensation
$562,053
Dr. Ambarish Shah Ph.D.
Chief Technology Officer
Mr. Dietrich John Pauls MBA
President, Chief Executive Officer & Director
Compensation
$917,475
DiaMedica Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $32.45M worth of DMAC shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
1.1M
7.63M
0
0.00
+7.6M
+$7.63M
9-12 Months
6.2M
24.82M
0
0.00
+24.8M
+$24.82M
Top Buyers
Stahlberg Jan
10 Percent Owner
$18.99M
Von Koch Thomas
10 Percent Owner
$10.00M
Krop Julie
Officer: Chief Marketing Officer
$2.06M
Jacinto Richard Ii
10 Percent Owner
$1.40M
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $32.45M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
4 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
DMAC - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 01, 2026 | May 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | March 28, 2025 | May 15, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 04, 2024 | May 22, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 04, 2023 | May 17, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 05, 2022 | May 18, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | June 03, 2021 | July 15, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 20, 2020 | June 02, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 08, 2019 | May 22, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.